MINK Therapeutics CEO Buell Buys 23,191 Shares, Signaling Insider Optimism Amid Volatile Biotech Landscape
CEO Buell’s latest buy of 23,191 MINK shares shows insider confidence in the company’s iNKT therapy pipeline, signaling potential upside amid a volatile market.
3 minutes to read